ID   2fTGH-U2A
AC   CVCL_M019
SY   U2A; U2
DR   cancercelllines; CVCL_M019
DR   CancerTools; 151807
DR   ECACC; 12021502
DR   Wikidata; Q54584473
DR   Ximbio; 151807
RX   PubMed=1837150;
RX   PubMed=1906577;
CC   Population: Caucasian.
CC   Characteristics: Unresponsive to alpha and beta interferons. Partially defective in response to interferon-gamma (PubMed=1906577).
CC   Characteristics: 2fTGH was derived from a HPRT negative subline of HT-1080. Expression of gpt is under the control of a IFN-alpha inducible IFI6 (6-16) promoter and is thus only expressed when IFN-alpha is present in the growth medium.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt.
CC   Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR).
CC   Transformant: ChEBI; CHEBI:132982; Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride; Acridine mutagen ICR 191).
CC   Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269.
ST   Source(s): ECACC
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 12,14
ST   D16S539: 9,12
ST   D5S818: 11,13
ST   D7S820: 9,10
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 14,19
DI   NCIt; C3043; Fibrosarcoma
DI   ORDO; Orphanet_2030; Fibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0115 ! 2fTGH
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 05-10-23; Version: 21
//
RX   PubMed=1837150; DOI=10.1073/pnas.88.24.11455;
RA   McKendry R., John J., Flavell D.M., Muller M., Kerr I.M., Stark G.R.;
RT   "High-frequency mutagenesis of human cells and characterization of a
RT   mutant unresponsive to both alpha and gamma interferons.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:11455-11459(1991).
//
RX   PubMed=1906577; DOI=10.1128/mcb.11.8.4189-4195.1991;
RA   John J., McKendry R., Pellegrini S., Flavell D.M., Kerr I.M.,
RA   Stark G.R.;
RT   "Isolation and characterization of a new mutant human cell line
RT   unresponsive to alpha and beta interferons.";
RL   Mol. Cell. Biol. 11:4189-4195(1991).
//